Jeffrey R. Rajkumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey R. Rajkumar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- April W. Armstrong
University of California, Los Angeles, USA
3 shared publications - Madison E. Jones
Keck School of Medicine University of Southern California Los Angeles CA USA
3 shared publications - Sarah P. Pourali
Vanderbilt University School of Medicine Nashville TN USA
3 shared publications - Yasmin Gutierrez
NYU Langone Health, New York, NY
3 shared publications Alison H. Kucharik
Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton FL USA
2 shared publications- Alan Schwartz
University of Illinois at Chicago
1 shared publication
Latest Publications
- 6 December 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (9) , 1056-1068
Are we contributing to the opioid epidemic? A systematic review on systemic opioid use in dermatology
Background: Although dermatologists treat many painful skin conditions and perform procedures that may require analgesic use, there is a lack of evidence synthesis on opioid use in dermatology.Objective: To conduct a systematic review of the evidence on the use of opioid analgesics in dermatology.Methods: We applied the PRISMA guidelines and systematically reviewed literature that examined opioid use in dermatology published between 1980 and 2020 in the PubMed, EMBASE, and Cochrane databases. This review was registered with PROSPERO (CRD42020204864).Results: We identified 24 studies that analyzed 52,705,201 patients and 13,099 dermatologists. Between 34% and 87.5% of patients received opioids following dermatologic procedures; however, many did not use the entirety of their prescriptions, and 35–69% did not use any of their prescription. Top opioid prescribers were more likely to be Mohs surgeons, male, and practice in the South. Variability exists in the current evidence for opioid prescribing for nonprocedural dermatologic disease.Conclusion: While opioid prescribing in dermatology is low compared with other specialties, patients are not utilizing the entirety of their prescriptions. Opioid prescribing for nonprocedural dermatologic disease varies; treatments focused on targeting the pathogenesis of these diseases is important to minimize opioid use. Dermatologists should consider limiting opioid prescribing and utilizing nonnarcotic analgesics.
- 6 December 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (9) , 1056-1068
Are we contributing to the opioid epidemic? A systematic review on systemic opioid use in dermatology
Background: Although dermatologists treat many painful skin conditions and perform procedures that may require analgesic use, there is a lack of evidence synthesis on opioid use in dermatology.Objective: To conduct a systematic review of the evidence on the use of opioid analgesics in dermatology.Methods: We applied the PRISMA guidelines and systematically reviewed literature that examined opioid use in dermatology published between 1980 and 2020 in the PubMed, EMBASE, and Cochrane databases. This review was registered with PROSPERO (CRD42020204864).Results: We identified 24 studies that analyzed 52,705,201 patients and 13,099 dermatologists. Between 34% and 87.5% of patients received opioids following dermatologic procedures; however, many did not use the entirety of their prescriptions, and 35–69% did not use any of their prescription. Top opioid prescribers were more likely to be Mohs surgeons, male, and practice in the South. Variability exists in the current evidence for opioid prescribing for nonprocedural dermatologic disease.Conclusion: While opioid prescribing in dermatology is low compared with other specialties, patients are not utilizing the entirety of their prescriptions. Opioid prescribing for nonprocedural dermatologic disease varies; treatments focused on targeting the pathogenesis of these diseases is important to minimize opioid use. Dermatologists should consider limiting opioid prescribing and utilizing nonnarcotic analgesics.
- 3 October 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (6) , e15150
Topical opioid use in dermatologic disease: A systematic review
Topical opioid formulations offer a potential solution to manage pain and decrease the use of systemic opioids. Synthesis of use and efficacy of topical opioids in dermatological conditions has not been well characterized. We conducted a systematic search of the PubMed, Embase, and Cochrane databases from 1980 to February 2021. This study analyzed data from 14 articles and 263 patients on the use of topical opioids for pain related to chronic ulcers, burns, oral lichen planus, photodynamic therapy, and split‐thickness skin grafts. Topical opioids included in this review were topical morphine and diamorphine. Common formulations consisted of 0.2–10 mg of opioid compounded with hydrogel or IntraSite gel. Topical opioids were variably effective in the use for pain control related to chronic ulcers and other dermatologic conditions. For example, the use of topical opioids appears to be effective in the reduction of pain related to pressure ulcers. Topical opioids were generally well tolerated. Insufficient data exist to adequately evaluate the efficacy and safety of topical opioid use in the context of nonpressure ulcers, burns, oral lichen planus, photodynamic therapy, and split‐thickness skin grafts.
- 3 October 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (6) , e15150
Topical opioid use in dermatologic disease: A systematic review
Topical opioid formulations offer a potential solution to manage pain and decrease the use of systemic opioids. Synthesis of use and efficacy of topical opioids in dermatological conditions has not been well characterized. We conducted a systematic search of the PubMed, Embase, and Cochrane databases from 1980 to February 2021. This study analyzed data from 14 articles and 263 patients on the use of topical opioids for pain related to chronic ulcers, burns, oral lichen planus, photodynamic therapy, and split‐thickness skin grafts. Topical opioids included in this review were topical morphine and diamorphine. Common formulations consisted of 0.2–10 mg of opioid compounded with hydrogel or IntraSite gel. Topical opioids were variably effective in the use for pain control related to chronic ulcers and other dermatologic conditions. For example, the use of topical opioids appears to be effective in the reduction of pain related to pressure ulcers. Topical opioids were generally well tolerated. Insufficient data exist to adequately evaluate the efficacy and safety of topical opioid use in the context of nonpressure ulcers, burns, oral lichen planus, photodynamic therapy, and split‐thickness skin grafts.
- 9 August 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (8) , E308-E309
Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns
- 9 August 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (8) , E308-E309
Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns
- 12 December 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (3) , 623-628
Combined antibiotic, steroid, and moisturizer for atopic dermatitis: A two‐year case series of patient‐reported outcomes
Background: Eczema treatments that target Staphylococcus aureus include topical mixtures of antimicrobial agent and corticosteroid diluted in a moisturizer base, previously described in the literature as compounded antibacterial, steroid, and moisturizer (CASM). There have been no placebo‐controlled blinded studies of CASM. Thus, patient‐reported outcome data may prove valuable.Objective: To determine the patient‐reported clinical course of eczema treatment with CASM.Methods: Longitudinal case series between May 2016 and August 2018 of CASM patients/parents. Patients completed surveys including the POEM measure at start of treatment, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months thereafter. Response curves were fitted to severity measures over time and compared by patient age group; survival analysis was used to estimate time‐to‐clear status as a function of patient age and initial severity.Results: A total of 2153 reports were received from 728 unique respondents with a median patient age of 7 and range of 0‐85. Response curves showed significant improvement over time leading to plateaus between 30 and 60 days of treatment. Overall mean improvement between start and day 90 for POEM was 14.3 (from 20.0 [95% CI 11.4‐28.8] to 5.7 [95% CI −3.2 to 14.8]). Improvement was seen in each age group.Conclusions: Patient‐reported outcomes suggest efficacy of CASM. There were large reductions in POEM scores, mostly in the first 30 days of treatment for all age groups.
- 12 December 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (3) , 623-628
Combined antibiotic, steroid, and moisturizer for atopic dermatitis: A two‐year case series of patient‐reported outcomes
Background: Eczema treatments that target Staphylococcus aureus include topical mixtures of antimicrobial agent and corticosteroid diluted in a moisturizer base, previously described in the literature as compounded antibacterial, steroid, and moisturizer (CASM). There have been no placebo‐controlled blinded studies of CASM. Thus, patient‐reported outcome data may prove valuable.Objective: To determine the patient‐reported clinical course of eczema treatment with CASM.Methods: Longitudinal case series between May 2016 and August 2018 of CASM patients/parents. Patients completed surveys including the POEM measure at start of treatment, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months thereafter. Response curves were fitted to severity measures over time and compared by patient age group; survival analysis was used to estimate time‐to‐clear status as a function of patient age and initial severity.Results: A total of 2153 reports were received from 728 unique respondents with a median patient age of 7 and range of 0‐85. Response curves showed significant improvement over time leading to plateaus between 30 and 60 days of treatment. Overall mean improvement between start and day 90 for POEM was 14.3 (from 20.0 [95% CI 11.4‐28.8] to 5.7 [95% CI −3.2 to 14.8]). Improvement was seen in each age group.Conclusions: Patient‐reported outcomes suggest efficacy of CASM. There were large reductions in POEM scores, mostly in the first 30 days of treatment for all age groups.